Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Lyu, Yu-Xuan
  • dc.contributor.author Muñoz Cánoves, Pura, 1962-
  • dc.contributor.author Bakula, Daniela
  • dc.date.accessioned 2025-03-28T12:36:36Z
  • dc.date.available 2025-03-28T12:36:36Z
  • dc.date.issued 2024
  • dc.description.abstract The recent unprecedented progress in ageing research and drug discovery brings together fundamental research and clinical applications to advance the goal of promoting healthy longevity in the human population. We, from the gathering at the Aging Research and Drug Discovery Meeting in 2023, summarised the latest developments in healthspan biotechnology, with a particular emphasis on artificial intelligence (AI), biomarkers and clocks, geroscience, and clinical trials and interventions for healthy longevity. Moreover, we provide an overview of academic research and the biotech industry focused on targeting ageing as the root of age-related diseases to combat multimorbidity and extend healthspan. We propose that the integration of generative AI, cutting-edge biological technology, and longevity medicine is essential for extending the productive and healthy human lifespan.
  • dc.description.sponsorship A.K.S. supported by grants from the Wellcome Trust (Investigator award 220784/Z/20/Z). B.K.P The Centre for Physical Activity Research (CFAS) is supported by TrygFonden (grants ID 101390, ID 20045, and ID 125132). C.C. was supported by the Oppenheimer Program, UCLA Jonsson Cancer Center Foundation, Margaret E. Early Medical Research Trust, and National Center for Advancing Translational Sciences UCLA Clinical and Translational Science Institute (CTSI) Grant UL1TR000124. D.C. was supported by NIH R01AG082105, R01DK 117481, R01AG063404, and R01AG 063389. E.C.T. was supported by an Irish Research Council Laureate Award IRCLA/2017/58 and Science Foundation Ireland Future Frontiers 19/FFP/6790. J.V. is funded by grants from the US National Institutes of Health (grants U19AG056278, U01HL145560, U01ES029519, P01AG017242, P01AG047200). J.P. would like to acknowledge NIH grants R01AG068048, R01AG82708, UG3CA268103, and P01 AG062413. J.L.K. is supported by the National Institutes of Health (grants R37AG013925 and R33AG061456), the Connor Fund, the Robert J. and Theresa W. Ryan Fund, and the Noaber Foundation. K.M. was supported by NEI of the National Institutes of Health no. 1R43EY034403-01. L.J.N. and P.D.R. are supported by NIH (R01AG063543, U19AG056278, U54AG076041, U54AG079754). M.H. is funded by Longevity Biotech Fellowship. M.Q. from Rubedo Life Sciences received award from California Institute of Regenerative Medicine (CIRM #DISC-14096) for its pharmacological program on targeting senescent lung stem cells in Idiopathic Pulmonary Fibrosis. P.M. is funded from grant number ERC-2016-AdG-741966. Q.F. received a grant from the Shandong Provincial Natural Science Foundation (ZR2023MH262), Yantai Double Hundred Program, University and Locality Collaborative Program (2021XDHZ082). S.L. was supported by the Healthy Longevity Catalyst Awards (Hong Kong): National Academy of Medicine, USA. T.A.R. are supported by grants from NIH AG68667 and AG82764. V.G. is supported by grants from the US National Institute on Aging, Impetus grants, Michael Antonov Foundation. V.S. research is supported by the NUHS Internal Grant Funding under NUS Start-up grant NUHSRO/2022/047/Startup/11. Y.-X. L. is supported by grants from the Southern University of Science and Technology, China, and from the Max Planck Society, Germany.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Lyu YX, Fu Q, Wilczok D, Ying K, King A, Antebi A, et al. Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity. Aging (Albany NY). 2024 Oct 16;16(20):12955-76. DOI: 10.18632/aging.206135
  • dc.identifier.doi http://dx.doi.org/10.18632/aging.206135
  • dc.identifier.issn 1945-4589
  • dc.identifier.uri http://hdl.handle.net/10230/70041
  • dc.language.iso eng
  • dc.publisher Impact Journals
  • dc.relation.ispartof Aging (Albany NY). 2024 Oct 16;16(20):12955-76
  • dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/741966
  • dc.rights © 2024 Lyu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by/4.0/
  • dc.subject.keyword Artificial intelligence
  • dc.subject.keyword Biotechnology
  • dc.subject.keyword Healthy longevity
  • dc.title Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Departament de Medicina i Ciències de la Vida)
Documents OpenAIRE (Open Access Infrastructure for Research in Europe)